Login to Your Account



Could Help Fill Vioxx Gap

NicOx Placement Gets $29.8M To Advance CINOD Compound

By Randall Osborne


Wednesday, October 6, 2004
Almost exactly a year after AstraZeneca plc quit its deal with NicOx SA for COX-inhibiting nitric oxide-donating (CINOD) drugs, NicOx said it expects to net about €24 million (US$29.8 million) through a private placement that will be used mainly to advance a lead compound from that program. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription